← All trials
NCT04787211
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 20, 2021
- Primary completion
- Dec 31, 2021
- Completion date
- Dec 31, 2021
- First posted
- Mar 8, 2021
- Last posted
- Aug 30, 2021
- Enrollment
- 24
- Arms / groups
- 3 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Brii BiosciencesLead sponsor
- Government of ChinaStudy director
- Government of ChinaCollaborator
- Capital Medical UniversityOverall official - principal investigator
- Guangzhou Medical UniversityOverall official - principal investigator
- Guangzhou Medical UniversityStudy chair
- Nanjing UniversityOverall official - principal investigator
- Shenzhen Third People's HospitalOverall official - principal investigator
- Yunnan Provincial Infectious Disease HospitalOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.